Spyre reports Q3 2026 results, SPY003 data complete IBD monotherapy trioNov 3Quarterly updateSPY002-072SPY003
Spyre Therapeutics files preliminary prospectus for common stock offeringOct 5FinancingSpyre Therapeutics, Inc.
Spyre reports positive Phase 2 SPY003 data, completing proof-of-concept for IBD trioSep 8Clinical readoutSPY001SPY002
Spyre reports Phase 2 IBD data for SPY001, SPY002, sets Q4 rheumatic readoutsAug 4Quarterly updateSPY001SPY002